Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6912 in healthy volunteers
NCT06115967Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Primary completion
- Oct 2025
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of AZD6912 in rheumatoid arthritis (RA) (9 arms), sponsored by AstraZeneca. Primary endpoint: Adverse Events at 38 weeks. Started Nov 2023; status: completed.
02
Drugs
AZD6912
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06115967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06115967.